A fluorescence in-situ hybridization (FISH) method will be further developed and utilized as a major procedure for the high resolution quantitation of the frequency of cycling AML cells. AML diseases associated with the following chromosomal abnormalities will be studied by this procedure - inv(16), t8;21, t15;17, +8, and -7. The procedure is based on our results in CML where we have coupled long term mitotic arrest to produce thousands of metaphases/slide (""""""""hypermetaphase"""""""") with the use of a FISH probe that detects the chromosomal rearrangement associated with the malignancy (hypermetaphase/FISH or HMF). In the CML model we have demonstrated that cancer cells could be readily quantitated in cycling cells from patient bone marrow preparations. The procedures will allow detection of <1% cancer, calls and will permit monitoring of <4% changes in the frequency of such cells. The methodology will be applied here to identify severity of disease in AML patients at diagnosis and to evaluate the effectiveness of therapies on AML patients during treatment. The data from +8 and -7 will be correlated with the interphase FISH data on those same samples generated by Core C. In addition we will conduct reverse transcription followed by PCR (RT/PCR) to determine the level of chimeric transcript in t15;17 and t8;21 AMLs to correlate with the HMF data as well as the interphase FISH and standard G-band cytogenetics (CG) data generated on the same samples by Core Finally we will complete development and conduct genomic PCR on inv(16) samples to evaluate the level of cells containing the chimeric gene reactive to our HMF results as well as RT/PCR, interphase FISH and CG conducted on those same samples. The experiments and correlations will be evaluated with the progress of the patients determined by Projects 1 and 2 (Drs.Estey and Champlin respectively) to determine the benefits and shortcomings of each of the technologies in establishing the cytogenetic response of patients to therapies involved. These procedures will give us new insights into determining the clinically significant level of residual disease, and guide the further management of individual malignancies in AML patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055164-07
Application #
6269507
Study Section
Project Start
1998-06-05
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Jiang, Xuejie; Mak, Po Yee; Mu, Hong et al. (2018) Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24:2417-2429
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Carter, Bing Z; Mak, Po Yee; Wang, Xiangmeng et al. (2017) Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16:1133-1144
Zeng, Zhihong; Liu, Wenbin; Tsao, Twee et al. (2017) High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 102:1537-1548
Pan, Rongqing; Ruvolo, Vivian; Mu, Hong et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell 32:748-760.e6
Jacamo, Rodrigo; Davis, R Eric; Ling, Xiaoyang et al. (2017) Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget 8:83354-83369

Showing the most recent 10 out of 422 publications